Spravato

Published research on Spravato.

DrugsMay 21, 2026

Esketamine Failed Cost-Effectiveness vs. Cheaper TRD Options at $50K/QALY

Intranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling st…

Read article →

DrugsMay 17, 2026

Esketamine Can Trigger Trauma Re-Experiencing in PTSD

A 2026 retrospective case series of 22 adults with treatment-resistant depression and comorbid PTSD found that trauma re-experiencing during intranasal esketamine disappeared over later sess…

Read article →

AddictionMay 1, 2026

Ketamine Addiction After One Therapeutic Dose: How Rare Is It?

Ketamine and its S-enantiomer esketamine (sold as Spravato) are now established treatments for treatment-resistant depression and acute suicidality. The standard safety pitch from sponsors a…

Read article →